BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Marengo Therapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Marengo Therapeutics\, Inc.'s dru
 gs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06827613-2742@assetmemo.bio
DTSTAMP:20261121T005943Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Invikafusp alfa: Phase 1/2 readout est. (NCT06827613)
DESCRIPTION:Invikafusp alfa\, phase 1/2\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: A Study of Invikafusp Alfa (STAR0602)\, a Selective T Cell Rece
 ptor (TCR)-Targeting\, Bifunctional Antibody-fusion Molecule\, in Combinat
 ion With Sacituzumab Govitecan in Participants With Advanced Solid Tumors\
 nEstimated primary completion: January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/invikafusp-alfa#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06827613
URL:https://assetmemo.bio/drug/invikafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05592626-2742@assetmemo.bio
DTSTAMP:20261121T005943Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Invikafusp alfa: Phase 1/2 readout est. (NCT05592626)
DESCRIPTION:Invikafusp alfa\, phase 1/2\, Non-Small Cell Lung Cancer.\nStud
 y: A Study of a Selective T Cell Receptor (TCR) Targeting\, Bifunctional A
 ntibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumor
 s\nEstimated primary completion: September 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/invikafusp-alfa#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05592626
URL:https://assetmemo.bio/drug/invikafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
